Medical oncologists provide comprehensive insights on treatment practices for patients with extended-stage small cell lung cancer.
Novel CAR T-cell Therapy Shows Best Overall PR in R/R SCLC and LCNEC
Safety and efficacy were noted with LB2102 for patients with small cell lung cancer and large cell neuroendocrine carcinoma.
Considering Dosing and AE Management Strategies With Tarlatamab in SCLC
Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.
Camrelizumab/Apatinib Plus Chemotherapy May Show Promise in ES-SCLC
The safety profile of camrelizumab plus apatinib and chemotherapy in a phase 1 study aligns with prior reports of each agent.
Updated ASCO Guidelines for Optimal Small Cell Lung Cancer Management
Practices are on the cusp of better understanding small cell lung cancer that in turn can help to advance treatment strategies for patients, says Gregory Peter Kalemkerian, MD.
ZL-1310 Receives FDA Fast Track Designation for Extensive-Stage SCLC
3 Things You Should Know About the Multimodal Treatment of SCLC
Here are 3 things you should know about the multimodal treatment of patients with SCLC.